Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

University Hospital, Essen180 enrolled

Overview

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Cardiotoxicity Breast Cancer Heart Failure

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * initial diagnosis of breast cancer * planned Anthracycline-based therapy * first-line chemotherapy * first visit before initiation of chemotherapy Exclusion Criteria: * previous chemotherapy * medical history of cardiac disease * inflammation-modulating medication * medication with RAS inhibitors * pregnancy * autoimmune disease * drug addictions * unwilling or unable to provide informed consent

Outcomes

Primary Outcomes

Cardiotoxicity during observational period

Defined according to IC-OS 2021 Consensus Criteria

Time frame: continuous evaluation during observational period of 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.